Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: shust who wrote (1380)	2/25/1999 4:59:00 PM
From: Anthony Wong	Respond to of 2539

This is old news reported on Feb 11 & 13, see #reply-8014504 & #reply-7772590 & also #reply-7811331 Analysts already knew about this, and some are concerned that Searle would become a one-drug company. Not true, though.

To: shust who wrote (1380)	2/25/1999 5:21:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 2539

Searle's pipeline: searlehealthnet.com

To: shust who wrote (1380)	2/25/1999 6:49:00 PM
From: Anthony Wong	Respond to of 2539

These two cancer drugs are not expected to be blockbusters: Monsanto, based in St. Louis, rose 7/16 to 48. Monsanto said it is continuing with another cancer drug, Leridistim. This drug is in so-called Phase III, the last of the three stages of required testing. Intended to stimulate bone marrow recovery in chemotherapy patients, this drug could someday have sales of $500 million, said Brakel, who has a ''hold'' rating on Monsanto. Celebrex, the first of a class of so-called Cox-2 drugs, is being tested for use in preventing colon cancer. Brakel said sales could eventually reach of $2 billion. Monsanto also is working on experimental drugs similar to Celebrex. The two drugs Monsanto has dropped would only have reached sales of about $100 million to $200 million each at best, Brakel said. Excerpted from a Bloomberg report: news.com